T0	Participants 85 100	vivo in humans.
T1	Participants 269 276	humans.
T2	Participants 461 527	higher insulin dosing in obese subjects than lean subjects (30 vs.
T3	Participants 528 562	10 mU.m(-2).min(-1), respectively)